Global Human Papilloma Virus (HPV) Vaccine Market Size, Share, Opportunities, And Type (Quadrivalent HPV Vaccine, Bivalent HPV Vaccine, 9-Valent HPV Vaccine), By Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Vulvar Cancer, Mouth Cancer, Genital Warts), By Gender (Male. Female), And By Geography - Forecasts From 2025 To 2030

Human Papilloma Virus (HPV) Vaccine Market Size:

The human papilloma virus (HPV) market is expected to grow from US$7.464 billion in 2025 to US$10.909 billion in 2030, at a CAGR of 7.89%.

Along with other immunizations, routine vaccination is advised for all nations according to WHO guidelines. The Human Papilloma Virus (HPV) vaccine offers defense against specific strains of the virus that can cause genital warts or cancer. Along with other immunizations, routine vaccination is advised for all nations according to WHO guidelines. These vaccinations are regarded as safe and effective medications and are included on the "World Health Organization's list of Essential Medicines." The global market for the Human Papilloma Virus (HPV) vaccine is being boosted by the rise in cervical cancer cases. Increased government measures will increase public awareness of HPV and cervical cancer, which will help the market for HPV vaccines. However, a stringent regulatory licensing procedure for the vaccines may limit market expansion.

Human Papilloma Virus (HPV) Vaccine Market Driver:

• Effectiveness of HPV Vaccines to Boost Sales

The effectiveness and protection offered by HPV vaccines to lessen the negative effects associated with such infections are one of the most important and significant market drivers. Clinical trials have demonstrated the effectiveness and safety of both bivalent and polyvalent vaccinations in preventing HPV infections and cancer. Additionally, it is projected that the rising incidence of cervical cancer in various nations would boost sales of the human papillomavirus vaccine, resulting in a stellar market expansion. The market is also being driven by an increase in HPV vaccination production capacity to keep global supply and demand in balance.

Human Papilloma Virus (HPV) Vaccine Market Geographical Outlook:

Geographically, the Human Papilloma Virus Vaccine Market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America holds major share of the market whereas Asia-Pacific is anticipated to have a faster-growing market.

Human Papilloma Virus (HPV) Vaccine Market Product Offerings:

• GARDASIL 9 vaccine: GARDASIL 9 vaccine by Merck is a vaccination that is recommended for females between the ages of 9 and 45 for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 causing cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers and Types 6, 11, and 6 and 11 of the HPV are also responsible for genital warts. GARDASIL 9 is recommended for use in males between the ages of 9 and 45 in order to prevent genital warts brought on by HPV Types 6 and 11, as well as anal, oropharyngeal, and other head and neck malignancies brought on by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Based on its effectiveness in preventing HPV-related anogenital disease, the accelerated approval process has authorized the indication for oropharyngeal and head and neck cancer.
• Cervarix vaccine: The GlaxoSmithKline-produced vaccine Cervarix is recommended for use starting at age 9 in order to prevent premalignant anogenital lesions (cervical, vulvar, vaginal, and anal cancers), as well as cervical and anal cancers that are connected to specific oncogenic Human Papillomavirus (HPV) types ( HPV 16 and 18). Cervarix is used for deltoid intramuscular injection. It has been demonstrated that the Cervarix vaccine shields women from a significant portion of the precursor lesions of cervical cancer brought on by these two HPV strains.

Human Papilloma Virus (HPV) Vaccine Market Scope:

Report Metric	Details
Human Papilloma Virus (HPV) Vaccine Market Size in 2025	US$7.464 billion
Human Papilloma Virus (HPV) Vaccine Market Size in 2030	US$10.909 billion
Growth Rate	CAGR of 7.89%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Type Indication Gender Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in Human Papilloma Virus (HPV) Vaccine Market	Merck & Co Inc. GSK plc INOVIO Pharmaceuticals Inc.
Customization Scope	Free report customization with purchase

 

The human papilloma virus (hpv) vaccine market is analyzed into the following segments:

• By Type
  • Quadrivalent HPV Vaccine
  • Bivalent HPV Vaccine
  • 9-Valent HPV Vaccine
• By Indication
  • Cervical Cancer
  • Anal Cancer
  • Vaginal Cancer
  • Vulvar Cancer
  • Mouth Cancer
  • Genital Warts
• By Gender
  • Male
  • Female
• By Geography
  • North America
    • USA
    • Mexico
    • Canada
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. COVID-19 Scenario

1.3. Market Definition

1.4. Market Segmentation

 

2. RESEARCH METHODOLOGY

2.1. Research Data

2.2. Assumptions

 

3. EXECUTIVE SUMMARY

3.1. Research Highlights

 

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

 

5. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET ANALYSIS, BY TYPE

5.1. Introduction

5.2. Quadrivalent HPV Vaccine

5.3. Bivalent HPV vaccine

5.4. 9-Valent HPV Vaccine

 

6. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET ANALYSIS, BY INDICATION

6.1. Introduction

6.2. Cervical Cancer

6.3. Anal Cancer

6.4. Vaginal Cancer

6.5. Vulvar Cancer

6.6. Genital Cancer

6.7. Others

 

7. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET ANALYSIS, BY GENDER

7.1.  Introduction

7.2. Male

7.3. Female

 

8. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET ANALYSIS, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germany

8.4.2. France

8.4.3. United Kingdom

8.4.4. Italy

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. India

8.6.4. South Korea

8.6.5. Taiwan

8.6.6. Thailand

8.6.7. Indonesia

8.6.8. Others

 

9. COMPETITIVE INTELLIGENCE

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

 

10. COMPANY PROFILES

10.1. Merck & Co., Inc.

10.2. GSK plc

10.3. INOVIO  Pharmaceuticals 

Merck & Co Inc.

GSK plc

INOVIO Pharmaceuticals Inc.